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High glucose transporter 1 (Glut1) surface expression is associated with
increased glycolytic activity in activated CD4+ T cells. Phosphatidylinositide
3-kinases (PI3K) activation measured by p-Akt and OX40 is elevated in
CD4+Glut1+ T cells from HIV+ subjects. TCR engagement of CD4+Glut1+
T cells from HIV+ subjects demonstrates hyperresponsive PI3K-mammalian
target of rapamycin signaling. High basal Glut1 and OX40 on CD4+ T cells
from combination antiretroviral therapy (cART)-treated HIV+ patients repre-
sent a sufficiently metabolically active state permissive for HIV infection
in vitro without external stimuli. The majority of CD4+OX40+ T cells
express Glut1, thus OX40 rather than Glut1 itself may facilitate HIV infec-
tion. Furthermore, infection of CD4+ T cells is limited by p110c PI3K inhibi-
tion. Modulating glucose metabolism may limit cellular activation and
prevent residual HIV replication in ‘virologically suppressed’ cART-treated
HIV+ persons.
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HIV is a retrovirus that relies on the host cell to synthesize
large amounts of viral proteins, RNA, and DNA, all of
which are essential for viral replication, integration, and
dissemination. The energy required to synthesize such
biomolecules, as well as the lipid bilayer surrounding the
viral genome, is predominantly provided by increased
glucose uptake and glycolytic metabolism [1,2]. Recent
studies have also shown that other viruses such as human
cytomegalovirus (HCMV) induce glycolytic metabolism
in host cells to support viral replication [3,4].
Abbreviations
BMI, body mass index; cART, combination antiretroviral therapy; CFSE, carboxyfluorescein diacetate succinimidyl ester; ECAR, extracellular
acidification rate; EGFP, enhanced green fluorescent protein; Glut1, glucose transporter 1; HCMV, human cytomegalovirus; mTOR, mam-
malian target of rapamycin; PI3K, phosphatidylinositide 3-kinases; RT, reverse transcriptase.
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Although activated T cells utilize a variety of energy
sources (e.g., glycogen, fatty acids, and amino acids),
glucose is considered to be the key energy source for
their growth, survival, differentiation, and effector
functions [5–8]. Greater metabolic demands are placed
on virus-infected cells. In meeting these imposed chal-
lenges, glucose is taken up by glucose transporters and
is converted to pyruvate through the glycolysis path-
way. Most of the pyruvate is converted to fatty acids
for membrane biosynthesis via a process known as
citrate cataplerosis [4].
Glucose transporter 1 (Glut1) is the primary glucose
transporter on T cells and its cell surface expression is
a reflection of the activation state of CD4+ T cells
[9,10]. This metabolically activated state makes the cell
more permissive to infection by HIV [11]. It has been
shown that activated immune cells increase surface
expression of Glut1 as a functional response to their
metabolic requirements [12]. Impairment of this pro-
cess can impact on the survival, differentiation, and
immunologic function of T cells [13,14], and a growing
body of evidence supports the notion that immunity
and inflammation are dependent on glucose metabo-
lism (reviewed in ref. [15–19]) [20]. We have recently
shown that increased expression of Glut1 on CD4+ T
cells in HIV-infected individuals is associated with
immune activation and CD4+ T cell loss [9]. Once acti-
vated, T cells undergo a metabolic switch in which glu-
cose is principally metabolized via aerobic glycolysis to
support growth, proliferation, and effector functions
[21–23]. The transport of glucose by Glut1 across the
hydrophobic cell membrane is the first and rate-limit-
ing step of glucose metabolism. The posttranscrip-
tional regulation of Glut1 is controlled, in part, by the
phosphatidylinositide 3-kinases (PI3K), the serine–
threonine kinase, Akt (also known as protein kinase
B), and the mammalian target of rapamycin (mTOR).
However, Glut1 can also be transcriptionally regulated
by the stress-responsive hypoxia inducible factor 1
alpha [24,25].
Glucose transporter 1 is a downstream target of the
PI3K–Akt pathway and, once activated, this trans-
porter is translocated from the cytoplasm to the cell
surface membrane to facilitate increased glucose
uptake and metabolism. Class IB PI3K is made up of
the p110c catalytic and p110d regulatory subunits.
These isoforms differ from other PI3K subunits in that
they have ‘tissue-restricted expression’ and are pre-
dominantly expressed in white blood cells [26–28]. Sev-
eral studies have confirmed the role of the PI3K–Akt
pathway in Glut1 regulation and in the metabolic reg-
ulation of T cells, for example, in response to activat-
ing stimuli in vitro [5,22,29,30]. However, the role of
specific isoforms in regulating Glut1 expression on
CD4+ T cells in humans remains unclear.
In this study, we used phospho-flow analysis to eval-
uate the activation status of the PI3K–Akt pathway in
Glut1-expressing CD4+ T cells from HIV-infected indi-
viduals who were treatment naive or combination
antiretroviral therapy treated (cART-treated). We also
measured the levels of cell-associated HIV DNA in
Glut1+ and Glut1 CD4+ T cells of these individuals.
Identification of molecules that regulate key steps in
glucose metabolism in CD4+ T cells will improve our
understanding of the metabolic pathways that might
contribute to HIV disease progression and persistence.
Methods
Participant recruitment and blood separation
The main study population included 10 HIV-infected
(HIV+) untreated individuals from the Clinical Research
Core Repository at the University of Washington, Seattle,
USA, who were subsequently placed on cART. Viable cry-
opreserved peripheral blood mononuclear cells (PBMCs)
(originally collected in EDTA anticoagulant) were shipped
in liquid phase nitrogen to Melbourne (Australia) from Seat-
tle. Anthropometric, clinical, and laboratory data were made
available for these subjects. Six HIV-seronegative control
subjects and seven HIV+ treatment-naive subjects were
recruited from the Burnet Institute and The Infectious Dis-
eases Unit at The Alfred Hospital, Melbourne, Victoria,
Australia. These HIV+ treatment-naive subjects contributed
samples for use in in vitro assays only. Informed consent was
obtained from all participants, and the research was
approved by the University of Washington Ethics Commit-
tee and The Alfred Hospital Research Ethics Committee.
Fresh blood samples from subjects recruited in Melbourne
were collected in citrate or EDTA anticoagulant tubes.
Exclusion criteria for participation included co-infection
with hepatitis C virus, active malignancy, vaccination, physi-
cal trauma, or surgery within 3 weeks prior to participation.
PBMCs from two HIV+ subjects included to enumerate total
cellular HIV DNA were obtained from the Immunovirology
Research Network repository in Sydney, Australia.
Flow cytometric analysis
White blood cells in fresh samples were immune-pheno-
typed within an hour of collection or cryopreserved as pre-
viously described [9,31]. Freshly isolated cells or thawed
PBMCs (> 90% viability) were stained on ice for 30 min in
the dark using the following pretitrated antibodies: CD3-
APC, CD4-PerCP, CD8-PE, CD38-PE, CCR5-APC, and
HLA-DR-FITC (all from BD Biosciences, North Ryde,
Australia). Analysis was performed on a FACSCalibur flow
3320 FEBS Letters 591 (2017) 3319–3332 ª 2017 The Authors. FEBS Letters published by John Wiley & Sons Ltd
on behalf of Federation of European Biochemical Societies
PI3K gamma subunit regulates HIV infection C. S. Palmer et al.
cytometer (BD Biosciences). At least 100 000 events were
acquired within the lymphocyte gate. FLOWJO software, ver-
sion 8.8 (Tree Star, Inc, Ashland, OR, USA) was utilized
for data analysis.
Glucose transporter 1 detection
Cell surface Glut1 expression on freshly isolated or cryop-
reserved PBMCs was measured by flow cytometry using
the Glut1 antibody [MAB1418 clone (R&D Systems, Min-
neapolis, MN, USA)], as previously described [9]. A pilot
analysis observing Glut1 expression on T cells revealed that
the cryopreservation and thawing process had no effect on
Glut1 expression or on the metabolic status of these cells.
Proliferation assay
PBMCs were resuspended at a concentration of
1 9 106 cellsmL1 in 1 9 PBS and incubated at 37 °C for
7 min with 2.5 lM carboxyfluorescein diacetate
succinimidyl ester (CFSE; Thermo Fisher Scientific, Wal-
tham, MA, USA). CFSE labeling was terminated by wash-
ing the cells three times with cold 1 9 PBS/0.5% FCS (v/
v). Cells were resuspended in 1 9 PBS and analyzed on a
FACSCalibur flow cytometer (BD Biosciences).
Western blot analysis
Samples were lysed and protein concentrations were
determined via a bicinchoninic acid protein assay
(Thermo Fisher Scientific). Lysates were solubilized and
10 lg protein loaded onto SDS PAGE gel, and Immu-
noblotting was performed as previously described [32],
using primary antibodies specific for phosphorylated Akt
(Ser473), and total Akt (all from Cell Signaling Technol-
ogy, Danvers, MA, USA). Images were detected with
enhanced chemiluminescence technique.
Extracellular flux analysis of glycolytic
metabolism
The Seahorse XFe-24 Extracellular Flux Analyser (Sea-
horse Biosciences, Billerica, MA, USA) was used to deter-
mine the basal rate of glycolysis of cells. Briefly, CD4+ T
cells were adhered to the bottom of the wells of a 24-well
Seahorse plate in assay buffer (unbuffered DMEM supple-
mented with 25 mM glucose and 1 mM sodium pyruvate,
pH 7.4) and equilibrated in buffer in a non-CO2 incubator
for 60 min prior to assay. The assay protocol consists of
repeated cycles of mixing (3 min), incubation (2 min), and
measurement (3 min) periods. Readings were taken after
16 min. Extracellular acidification rate (ECAR) was mea-
sured by excitation of fluorophores for H+, indicative of
nonoxidative metabolism.
HIV infection and DNA amplification
Viruses
The CXCR4-tropic NL4-3 HIV proviral DNA was obtained
through the NIH AIDS Research & Reference Reagent Pro-
gram (where it was originally deposited by Dr Malcolm
Martin) [33]. The CCR5-tropic NL4-3-AD8 HIV clone was
obtained through the AIDS Research and Reference
Reagent Program (originally from Dr Eric O. Freed) [34].
Enhanced green fluorescent protein (EGFP) was inserted
into the nef open-reading frame of NL4-3 or NL4-3-AD8
to generate NL4-3-Dnef-EGFP or NL4-3-AD8-Dnef-EGFP,
respectively. The pBR-NL4-3-IRES-EGFP-nef+ construct
[35] was kindly provided by Dr F. Kirchhoff (University of
Ulm, Germany).
HIV infection
CD4+ T cells from HIV+/cART subjects were infected with
NL4-3-Dnef-EGFP or NL4-3-AD8-Dnef-EGFP. Virus
infectivity was normalized by measuring HIV reverse tran-
scriptase (RT) activity via a micro-RT assay, as previously
described [36]. Samples were treated with virus for 2 h at
37°C, washed twice with cold 1 9 PBS, and resuspended in
RPMI 1640 supplemented with 10% FCS, 2 mM L-gluta-
mine (Invitrogen), penicillin/streptomycin (100 UmL1;
Invitrogen, Australia), and 5 ngmL1 of human inter-
leukin-2 (IL-2; R&D Systems). Cells were cultured for
3 days, and viral infection was determined by the detection
of GFP+ cells within the FL1 channel of a FACSCalibur.
HIV quantification in CD4+ T cells from
treatment-naive and cART-treated HIV+ subjects
CD4+ T cells were purified from PBMCs using the Human
EasySep CD4+ T cell enrichment kit (Stem Cell, Technol-
ogy Inc, Vancouver, BC, Canada), and lysates were
analyzed for total HIV DNA and integrated DNA using
real-time RT-PCR as previously described [37].
Phospho-flow and intracellular staining
PBMCswere thawed and resuspended in supplementedRPMI-
1640 medium and allowed to rest for 24 h at a concentration of
1 9 106 cellmL1 at 37 °C, 5%CO2. Cells were fixed and per-
meabilized using the IntraStain Kit (Agilent, Santa Clara, CA,
USA), and incubated with anti-p-Akt (T308)-PE antibody (BD
Biosciences) following recommended procedures from the
manufacturer. The cells were fixed with 0.5%PFA before anal-
ysis on a FACSCalibur (BDBiosciences).
Statistical analysis
Statistical analysis was performed using GRAPHPAD PRISM
statistical software (GraphPad Software, San Diego, CA,
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USA). The nonparametric Mann–Whitney t-test was used
for comparison tests of unpaired data and the paired t-test,
or the Wilcoxon matched-pairs signed-rank test was used
to test significance between paired data. Spearman rank test
was used for correlation analyses.
Results
Subject clinical characteristics
The demographic characteristics and clinical parame-
ters of patients and controls recruited into this study
are summarized in Table 1. A total of 16 subjects,
including 10 who were HIV+ and treatment naive
(HIV+/naive) and subsequently started on combination
antiretroviral therapy (HIV+/cART) and six who were
HIV seronegative (HIV), were recruited to evaluate
CD4+ T cell Glut1 cell surface expression and intracel-
lular PI3K–Akt signaling in thawed PBMCs. There
were no significant differences in body mass index
(BMI) or age between the HIV+ and HIV groups.
At the time of recruitment, the median CD4+ T cell
count in the HIV+/naive subjects was 223 cellslL1,
and this median count increased to 338 cellslL1 after
3.3 years (range: 2.1–4.0, P = 0.01) on cART.
Glut1 expression is associated with activation
and proliferation of CD4+ T cells
We confirmed glucose metabolic activation in our HIV-
positive groups by evaluating Glut1 expression on
CD4+ T cells. Figure 1A illustrates the gating strategy
used. Similar to previous report [9], the frequency of cir-
culating CD4+Glut1+ T cells was increased in HIV+
subjects and remained elevated above normal levels in
cART-treated individuals (Fig. 1B). To determine if
Glut1 expression is associated with activation, we deter-
mined the levels of activation markers CD38 and HLA-
DR on CD4+Glut1+ and CD4+Glut1 cells.
CD4+Glut1+ T cells from HIV-negative and HIV-posi-
tive subjects irrespective of treatment status had mod-
estly higher levels of activation markers HLA-DR
Table 1. Clinical characteristics of study groups.
Variables n
Groups P value
HIV (A) HIV+/naive (B) HIV+/cART (C) A vs B B vs C A vs C
Sex (M) 26 6 10 10 – – –
BMI (kgm2) 24 23.5 (22.0–25.8) 24.3 (20.4–33.1) 22.7 (18.9–34.7) 0.66 0.82 0.52
Age (years) 26 39.0 (33.0–49.0) 37.0 (28.5–53.2) 40.6 (30.7–55.3) 0.77 0.002 0.83
CD4+ T cell count (cellslL1) 20 – 223 (122.5–379.8) 338 (177.5–575.5) – 0.01 –
Time on cART (years) 10 – – 3.3 (2.1–4.0) – – –
% CD3+CD4+ T cells 26 53.8 (42.8–63.2) 29.3 (11.6–32.6) 37.2 (26.3–52.8) 0.0005 0.004 0.11
Viral load (copiesmL1) 20 – 91 900 (37 925–188 000) < 50 – – –
Continuous variables are expressed in median (interquartile range). The nonparametric Mann–Whitney t-test was used to evaluate significant
difference between the HIV group and the others. The Wilcoxon matched-pairs signed-rank test was used to evaluate significant differ-
ences between the HIV+/naive and HIV+/cART group. Bold numbers represent significant P values.
Fig. 1. Glut1 cell surface expression on CD4+ T cells is associated with markers of proliferation and activation. (A) Representative flow
cytometric dot plots of PBMCs from an HIV+/cART subject. Lymphocytes (circled) were defined using side scatter (SSC) and forward
scatter (FSC) characteristics. The gating strategy shows T cells defined based on CD4 and CD8 surface expression. A representative Glut1-
isotype, and Glut1 antibody staining on CD4+ T cells in peripheral blood from HIV+/cART subjects. (B) Percentage of CD4+Glut1+ T cells in
peripheral blood from HIV-negative, HIV+/naive, and HIV+/cART subjects (left panel). Same subjects as in left panel showing percentages of
CD4+Glut1+ T cells before and during cART (right panel). (C) Representative histogram (left panel) and aggregate plot (right panel) of HLA-
DR expression on CD4+Glut1+ and CD4+Glut1 T cell from HIV+ subjects. (D) Representative histogram (left panel) and aggregate plot
(right panel) of CD38 expression on CD4+Glut1+ and CD4+Glut1 T cell from HIV+ subjects. (E) Representative histogram (left panel) and
aggregate plot (right panel) of CCR5 expression on CD4+Glut1+ and CD4+Glut1 T cell from HIV+ subjects. 5 HIV and 5 HIV+ subjects
were analyzed for all surface markers. (F, G) Representative dot plots showing forward and side scatter properties of PBMCs from two HIV-
negative subject stimulated with 10 lgmL1 PHA plus 5 ngmL1 IL-2 for 4 days (blue dots), or cultured without stimulation for the same
amount of time (red dots) (left panel). (Right panels) Cells were labeled with CFSE on day 1 as described in Methods, and representative
plots of CFSE-labeled CD4+ T cells after 4 days of incubation with PHA plus IL-2 (blue line) or unstimulated (red line). (H) The bar chart
indicates the cumulative MFI of Glut1 relative to isotype control on CD4+ T cells within each corresponding peak (A–G) showing different
rounds of CD4+ T cell replication, and peak G (red) showing CD4+ T cells from unstimulated PBMCs. Cumulative results are obtained from
4 to 5 peaks depending on the amount of cell division. The paired t-test was used to measure significant differences within groups.
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(Fig. 1C) and CD38 (Fig. 1D), and the HIV co-recep-
tor, CCR5 (Fig. 1E) than did CD4+Glut1 T cells. To
determine if Glut1 expression is associated with prolifer-
ation of CD4+ T cells, Glut1 expression was evaluated
over time in dividing CD4+ T cells from uninfected
donors. Using CFSE-labeled PBMCs activated with
PHA and IL-2 for 4 days, higher cell surface Glut1
expression was observed on CD4+ T cells that had
undergone proliferation. Figure 1F,G is representative
dot plots from four subjects in independent experiments;
however, due to variations in the number of peaks in the
activated samples, the number of data points per peak
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in the aggregate graph (Fig. 1H) varied from 5 to 6
(Fig. 1F,G, right panels). Collectively, these data
suggest that Glut1 expression is associated with CD4+
T cell activation and proliferation.
The PI3K pathway is activated in CD4+Glut1+ T
cells
Activation of T cells induces PI3K activity that is
involved in Glut1 translocation from the cytoplasm to
the cell surface membrane [38]. Utilizing phospho-flow
technology, the percentage of CD4+Glut1+ T cells
expressing p-Akt (T308), a downstream effector of the
PI3K pathway, was found to be elevated in HIV+/
naive subjects compared with HIV controls (Fig. 2A,
B). Notably, CD4+Glut1+ T cells from HIV+/naive
and HIV+/cART subjects expressed significantly higher
p-Akt (T308) than did CD4+Glut1+ T cells from
HIV subjects (Fig. 2C). Furthermore, CD4+ T cells
from HIV+ subjects expressed significantly higher
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Fig. 2. Glut1 cell surface expression on CD4+ T cells is associated with high PI3K activity. (A) Individual comparisons of changes in the
percentage of CD4+Glut1+p-Akt (T308)+ T cells in peripheral blood of HIV+ subjects before and during cART. (B) Aggregate percentage of
CD4+Glut1+p-Akt (T308)+ T cells in peripheral blood from HIV, and HIV+ subjects before and during cART. (C) Geometric MFI of p-Akt
(T308) in Glut1 and Glut1+CD4+ T cells in PBMCs from HIV, and HIV+ subjects before and during cART. (D) Representative dot plots
showing percentage of CD4+Glut1+p-Akt (T308)+ T cells within the CD4+ T cell populations of PBMCs from HIV+ subjects stimulated with
anti-CD3/28 microbeads, and (E) showing cumulative data. (F) Representative histogram showing the shift in fluorescence intensity of p-Akt
(T308)-PE in CD4+ T cell compartments in PBMCs from HIV-negative and HIV+/cART subjects stimulated with anti-CD3/28 microbeads, with
cumulative data represented in (G). The error bars represent mean (SEM). The paired t-test and the Mann–Whitney t-tests were used to
measure significant differences within and between the groups, respectively.
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levels of p-Akt (T308) in response to anti-CD3/CD28
microbeads co-stimulation than did CD4+ T cells from
HIV individuals, illustrating a hypermetabolic
response (Fig. 2D,E).
We followed up these observations and showed that,
during in vitro activation of PBMCs from HIV and
HIV+/cART subjects, CD4+Glut1+ T cells expressed
higher levels of p-Akt (T308) than did CD4+Glut1 T
cells (Fig. 2F,G), consistent with higher PI3K activity.
CD4+Glut1+ T cells from patients are not
enriched for total HIV DNA
Since increased Glut1 expression on CD4+ T cells has
been shown to facilitate HIV infection [11], CD4+ T
cells from HIV+/naive and HIV+/cART subjects were
sort-purified into CD3+CD4+Glut1 and Glut1+ sub-
populations (Fig. 3A) and examined for total HIV
DNA content. CD3+CD4 T cells represent CD8+ T
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Fig. 3. CD4+Glut1+ cells take up more HIV in culture than do CD4+Glut1 T cells. (A) Representative flow cytometric dot plot showing the
cell surface expression of Glut1 on CD4+ T cells after being gated within the lymphocyte and CD3+ T cell population of PBMCs from HIV+/
naive or HIV+/cART subjects. The red square represents the gating strategy used to sort Glut1 from Glut1+ cells within the CD4+
population in order to analyze total cellular HIV DNA. (B, Left panel) Total HIV DNA in CD4+Glut1+ and CD4+Glut1 T cell populations in
HIV+/naive (n = 6) and HIV+/cART (n = 5) subjects. The blue line represents the detection limit of the assay. (B, Right panel) Combined data
for total HIV DNA levels in CD4+Glut1+ and CD4+Glut1 T cells from HIV+/naive or HIV+/cART subjects. (C) Representative dot plot of cells
gated on CD3+CD4+ T cells from PBMCs of HIV+/cART subjects cultured for 3 days in the absence of GFP-tagged HIV (n = 5). (D)
Representative histogram of OX40 on CD4+Glut1 and CD4+Glut1 cells from subjects in C (left panel), with cumulative data shown (right
panel). (E) Representative dot plot showing OX40 and Glut1 expression on cells gated on CD4+ T cells from PBMCs of HIV+/cART subjects
cultured for 3 days with GFP-labeled HIV. (F) Representative dot plots showing the percentages of GFP+ cells in CD4+Glut1+OX40+,
CD4+Glut1+OX40, and CD4+Glut1OX40 T cells. (G) Graph showing cumulative frequency of GFP+ cells within different populations of
CD4+ T cells based on their cell surface expression of Glut1 and OX40 (n = 5). The Wilcoxon matched-pairs signed-rank t-test was used to
evaluate significant differences between the levels of HIV DNA in CD4+Glut1+ and CD4+Glut1 T cells in HIV+/cART subjects. The Mann–
Whitney t-tests were used to measure significant differences in the percentage of GFP+ cells within the CD4+ T cell populations.
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cells which we have previously shown to express high
basal Glut1 levels [9]. This contrasts results from other
groups who have reported that Glut1 is undetectable
or is expressed at low levels in quiescent T cells
[12,39,40]. Thus, our results herein call into question
the interpretation of data obtained using different
Glut1 detection techniques, or the specificity of the
Glut1 antibody MAB1418 clone (R & D Systems), at
least for CD8+ T cells.
Although the total HIV DNA content was higher in
CD4+Glut1+ T cells than in Glut1 cells from some
patients, this was not universal (Fig. 3B), suggesting
that Glut1 expression on CD4+ T cells might be driven
by other factors independent of direct HIV infection,
such as inflammatory cytokines as previously suggested
[38]. Of note, there were no clinically significant differ-
ences between Pt4 and the other subject in this analy-
sis. The percentage of CD4+Glut1+ T cells for each
subject is shown in Table S1.
Total HIV is predominantly found within
CD4+Glut1+OX40+ T cells in vitro
To determine whether levels of activation in unstimu-
lated CD4+Glut1+ T cells support HIV infection and
replication, we selected PBMCs from five virologically
suppressed HIV+/cART subjects who had a high per-
centage of CD4+Glut1+ T cells, four of whom had
undetectable cellular HIV DNA, and exposed them to a
GFP-tagged HIV in the absence of exogenous activating
stimuli. Since PI3K activity and Glut1 are reportedly
important for HIV infection in vitro [11], we reasoned
that CD4+Glut1+ T cells from those patients with high
PI3K activity might be preferential targets of HIV
in vitro. Figure 3C illustrates a dot plot of
CD4+Glut1 and CD4+Glut1+ T cells in PBMCs from
an HIV+/cART subject cultured for 3 days in the
absence of GFP-tagged HIV. Noticeably, OX40 expres-
sion was greater on Glut1-positive cells than on Glut1
cells (Fig. 3D). Examining OX40 expression on CD4+
T cells in HIV-negative and HIV+/cART subjects, we
observed increased frequency of CD4+OX40+ T cells in
anti-CD3/CD28-activated cells (P = 0.03; Fig. S1).
OX40 (CD134) is a member of the tumor necrosis
factor receptor superfamily, and its expression is a sur-
rogate marker of PI3K activity in T cells [41]; thus, we
anticipated that Glut1+OX40+ cells would be preferen-
tially infected by HIV in vitro. Figure 3E illustrates
that the majority of OX40+ cells express Glut1. HIV-
GFP+ cells were enriched within the CD4+Glu-
t1+OX40+ T cell population, with significantly less
infection in CD4+Glut1OX40 cells (Fig. 3F,G).
For this specific experiment, we were unable to include
a live/dead marker in this panel due to accessibility of
only a four color FACS instrument. However, we are
confident that most of the gated cells were viable
because, prior to staining, viability was > 95% as
assessed by trypan blue staining. Together, these
ex vitro data suggest that basal expression of Glut1
and P13K signaling in virologically suppressed cART-
treated HIV+ subjects represented a sufficiently acti-
vated cellular state permissible to HIV infection.
Inhibition of PI3K subunit, p110c, suppresses HIV
infection of CD4+ T cells in cell culture
We next wanted to determine whether pretreatment of
PBMCs from uninfected subjects with AS-605240
(AS), a specific inhibitor of the PI3K p110c isoform
[42–44], would affect HIV infection. Treatment of
PBMCs with AS reduced infection of CD4+ T cells by
either CXCR4-tropic (Fig. 4A–C,F) or CCR5-tropic
viruses (Fig. 4A,D–F). To confirm the metabolic
effects of AS, CD4+ T cells were activated in the pres-
ence or absence and absence of AS and Glut1 expres-
sion and glycolysis evaluated. We found that AS
modestly suppressed both Glut1 expression on CD4+
T cells (Fig. 4G,H) and the ECAR (indicative of gly-
colysis; Fig. 4I). Furthermore, phosphorylation of
Ser473-Akt (Fig. 4J), which is essential for activation
of the PI3K–Akt pathway, was suppressed but not
completely abrogated by AS treatment [45]. Collec-
tively these data suggest that the PI3Kc partially con-
trols the glucose metabolic components of CD4+ T
cells essential for efficient HIV infection [11,46].
Discussion
We have previously shown that the proportion of
CD4+ T cells that express Glut1 is significantly
increased in HIV-infected individuals and is associated
with increased glucose uptake and lactate production
by CD4+ T cells, as well as CD4+ T cell depletion
in vivo [9]. Here, we investigated a candidate Glut1
regulating pathway, PI3K–Akt, to evaluate its poten-
tial role in the regulation of Glut1 on CD4+ T cells in
HIV-infected subjects. We report a hyperresponsive
PI3K signaling in CD4+ T cells from HIV+ subjects
associated with increased phosphorylation of Akt
(T308). In vitro experiments also showed that a Glu-
t1+OX40 phenotype renders CD4+ T cells from
cART-treated HIV+ subjects permissive to HIV infec-
tion without external activating stimuli. CD4 infectiv-
ity by HIV was sensitive to PI3Kc inhibition.
Our work corroborates previous findings by Hege-
dus et al. and Loisel-Meyer et al. [11,47] based on
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in vitro observations that Glut1-mediated glucose
metabolic pathways are critical regulators of HIV
infection in T cell lines and primary CD4+ T cells
[1,11], reflective of an altered metabolic profile favor-
ing viral infection and replication [1]. Recently, it has
been hypothesized that hyperactivation of aerobic gly-
colysis pathways in CD4+ T cells during HIV infec-
tion could foster apoptosis and accelerate their
destruction [46,48]. We extended this observation to
demonstrate the involvement of the specific PI3Kc in
metabolic activation and permissiveness of CD4+ T
cells to HIV. Furthermore, in the absence of external
stimuli, we identified a population of CD4+Glu-
t1+OX40+ cells that are preferentially infected. Note-
worthy, the overwhelming majority of CD4+OX40
cells co-express Glut1, suggesting that OX40 expres-
sion reflects a metabolic signature permissive to HIV
infection.
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Fig. 4. Inhibition of PI3Kc in CD4+ T cells suppresses glycolysis and HIV infection. Purified PBMCs for HIV subjects were pretreated for
48 h with 200 nM AS-605240 (AS) and activated with 10 lgmL1 PHA plus 5 ngmL1 IL-2 for 24 h prior to infection with either a CXCR4
or a CCR5 tropic virus. (A) PBMCs were activated but were not incubated with HIV. (B) PBMCs with no inhibitor prior to activation,
incubated with CXCR4 tropic HIV. (C) PBMCs pretreated with AS-605240 (AS) prior to activation and incubated with CXCR4 tropic HIV. (D)
PBMCs with no inhibitor prior to activation, incubated with CCR5 tropic virus. (E) PBMCs pretreated with AS-605240 (AS) prior to activation
and incubated with CCR5 tropic virus. (F) Combined data from three independent experiments showing the effects of PI3K subunit p110c
isoform inhibition on HIV infection. The Wilcoxon matched-pairs signed-rank t-test was used to evaluate significant differences between
treatments. (G, H) Negatively selected and purified CD4+ T cells from HIV controls were left untreated or treated with AS for 24 h
followed by activation with anti-CD3/CD28 beads (bead: cell ratio, 1 : 2), and Glut1 cell surface expression measured. Representative
histogram is indicated in panel G and shows the effect of AS on Glut1 expression. Activated cells were stained with isotype control.
Cumulative data are shown in panel H. The p38 MAP kinase inhibitor SB202190 (10 lM) was used as a nonmetabolic inhibitor control. (I)
ECAR of purified CD4+ T cells. Cells were either left unactivated (UT), or inhibited and activated as in G above. Bars graphs represent
mean  SD. Differences between individual groups were analyzed using the nonparametric two-tailed Mann–Whitney U test. Statistical
differences are indicated by P values above the plots. (J) Western blot analysis showing the effect of AS-605240 pretreatment on PI3K
activity (p-Ser473Akt) in anti-CD3/CD28-activated (Act) CD4+ T cells. Total Akt was used as a reference control.
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The finding of heightened expression of the high
affinity glucose transporter Glut1 on CD4+ T cells cor-
roborates previous studies, which demonstrated that
HIV infection in vitro was associated with elevated
glucose uptake and increased glycolysis [1,2,47]. Simi-
lar findings have been observed in infection with poly-
oma virus [49] and HCMV [4,50]. Our data
demonstrate that CD4+Glut1+ T cells from patients
were highly susceptible to HIV infection in vitro with-
out requiring additional activating stimuli. Unexpect-
edly, although there were marginally increased HIV
DNA in sorted CD4+Glut1+ T cells compared with
CD4+Glut1 T cells in some HIV+ subjects, this was
not universal and cumulative data showed no signifi-
cant differences. It is possible that HIV is confined to
distinct subpopulations of CD4+Glut1+ T cells, such
as resting memory T cells that express Glut1. Subjects
with a high percentage of CD4+Glut1+ T cells nor-
mally have a low CD4 T cell count [9] and, given con-
straints on the volume of blood that could be drawn
under the ethical guidelines, we were unable to acquire
sufficient numbers of cells to analyze specific subpopu-
lations of Glut1-expressing CD4+ T cells. Efforts to
measure HIV protein in CD4+ T cells from HIV+ sub-
jects in the absence of stimulation were also not forth-
coming. Thus, a limitation of this study was the
inability to precisely characterize HIV levels in specific
subpopulations of CD4+Glut1+ and CD4+Glut1 T
cells. Such characterization will broaden our under-
standing of HIV pathogenesis including the potential
role of glycolytic metabolism and PI3K-mTOR signal-
ing in HIV latency in specific CD4+ T cell subpopula-
tions. Of note, we found high levels of Glut1 binding
on CD8+ T cells using the MAB1418 antibody clone
from R&D systems. This contradicts other groups who
have reported the absence of Glut1 on quiescent
CD8+ T cells [12,39,40]. In a previous study, we found
that CD4+ T cells reactive to the MAB1418 clone took
up more glucose and produced more lactate compared
with nonreactive cells [9]. This suggests that the
MAB1418 clone may at least in part define a state of
high metabolic activity in activated CD4+ T cells.
However, since several authors reported that Glut1 is
not expressed on resting CD8+ T cells, this contro-
versy warrants clarification and remains to be resolved
in future studies.
Phospho-flow analysis showed a high level of phos-
phorylation of Akt at T308 (indicative of PI3K activa-
tion) in CD4+Glut1+ T cells, demonstrating that
PI3K–Akt pathway contributes at least partly to the
increased glucose metabolism in CD4+ T cells in HIV+
individuals and corroborating previous findings that
activation of the PI3K–Akt pathway is considered an
important switch to activate metabolic programs char-
acteristic of activated and proliferating T cells
[22,51,52]. An interesting novel observation is that
CD4+ T cells from HIV+ subjects exhibit PI3K-direc-
ted metabolic hyperactivation, a phenomenon similar
to that described by monocytes rechallenged with Can-
dida albicans cell wall constituent b-glucan, termed
monocyte memory or trained immunity [53].
In in vitro experiment described by Loisel-Meyer
et al. [11], inhibition of cytokine-induced Glut1 expres-
sion and PI3K activation on CD4+T cells by the non-
isoform and non-tissue-specific PI3K inhibitor,
LY294002 [54,55], caused complete abrogation of sin-
gle-round HIV infection. We have extended these
observations and showed that inhibition of the specific
PI3K isoform, PI3Kc, prior to HIV exposure signifi-
cantly reduced HIV infection of CD4+ T cells, an
observation that may be explained by the requirement
of PI3Kc kinase activity for efficient Akt phosphoryla-
tion/activation, optimal T cell activation, and cell cycle
progression [26]. Furthermore, we observed that
PI3Kc inhibition using AS-605240 modestly sup-
pressed Glut1 on CD4+ T cells. This is in line with the
western blot analysis which showed that PI3Kc inhibi-
tion did not completely abrogate PI3K–Akt signaling
as measured by p-Akt(Ser473). This contrasts results
from Barata et al. [45] who demonstrated complete
abrogation of Akt(Ser473) phosphorylation and total
Glut1 in IL-7 treated TAIL7 cell lines exposed to
LY294002. With inference from above, LY294002 may
nonspecifically inhibit other PI3K isoforms or net-
works that also regulate Glut1 cell surface expression
on CD4+ T cells. Furthermore, the choice of cell types,
activating stimuli, activation status, and concentration
of inhibitors distinguished our work from those
described above. In closer agreement with our findings,
it has been shown that LY294002, PP242 (PI3K/
mTOR kinase inhibitor), and rapamycin (mTORC1
inhibitor) suppressed, but did not abrogate the anti-
CD3/CD28-induced cell surface Glut1 expression in T
cells [10]. Taken together our data suggest that thera-
peutic targeting of the PI3Kc isoform in CD4+ T cells
is likely to be more specific since this isoform is prefer-
entially expressed in leukocytes [26–28].
It may seem counterintuitive that T cells that have a
markedly increased demand for energy would be
involved in exploiting a relatively inefficient means like
glycolysis to generate ATP. However, the shift from
oxidative phosphorylation to aerobic glycolysis by
rapidly proliferating T cells diverts the use of glucose
carbon for macromolecular biosynthesis [46,52,56].
Thus, it has been proposed that increased glycolysis in
CD4+ T cells may render them preferential targets for
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HIV infection [46]. Interestingly, PI3K signaling is
tightly coupled to mTOR activity, recently shown to
regulate HIV latency [57] and control production of
pro-inflammatory cytokines from activated CD4+ T
cells [58]. Indeed, inhibition of PI3K and mTOR1/2
has been shown to suppress HIV reactivation and repli-
cation, including multidrug resistant strains by reduc-
ing cellular biosynthesis [59,60]. Our findings support
therapeutic targeting metabolism through the OX40-
PI3Kc axis in CD4+ T cells to reduce metabolic activity
necessary for HIV reactivation and homeostatic prolif-
eration of the CD4+ T cell-restricted HIV reservoir.
Furthermore, the observation that CD4+ T cells from
cART-treated HIV positive individuals are metaboli-
cally hyperactive supports the ‘block and lock’ [57] and
‘starve’ [15] HIV cure strategies recently proposed.
In summary, we highlighted for the first time a
hyperactive glucose metabolism in CD4+ T cells, and
the existence of a population of metabolically active
CD4+OX40+ T cells from cART-treated HIV+
patients highly susceptible to HIV infection. PI3Kc-
directed inhibition may promote targeted reduction of
CD4+ T cell metabolic activation in HIV infection and
other inflammatory conditions associated with CD4+
T cells hypermetabolic responses.
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